CARCINOGENIC GLUTAMIC-ACID PYROLYSIS PRODUCT IN THE DIALYSATE OF UREMIC PATIENTS TREATED BY CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS

  • 1 August 1988
    • journal article
    • research article
    • Vol. 30  (2) , 73-78
Abstract
By using a high-performance liquid chromatography (HPLC) method, we determined the contents of 2-amino-6-methydipylrido[1,2-a:3'', 2''-d] imidazole (Glu-P-1) and 2-aminodipyrido[1,2-a:3'', 2''-d]imidazole (Glu-P-2) in the dialysate of patients with uremia. The total dialysate (approximately 6 liters) per day of the patients who had received continuous ambulatory peritoneal dialysis (CAPD) was examined. The amounts of Glu-P-1 and Glu-P-2 in the total dialysate per day were 55.2. .+-. 266.9 pmole and 386.3 .+-. 146.0 pmole (mean .+-. SD, n = 10), respectively. The recoveries of Glu-P-1 and Glu-P-2 in the dialysate on our assay method were 68.2% and 54.3%, respectively. Based on the recoveries, the average amounts of Glu-P-1 and Glu-P-2 in the dialysate of uremic patients were assumed to be 809.7 pmole and 711.4 pmole, respectively.